Alicia Hammond from Brooklyn, New York, was on the brink of death due to severe obesity, but our latest product saved her life
Gastroparesis is also a less common, but potentially severe side effect of GLP-1 medications
doi: 10.1111/cen.12766 152 MilnerKMCraigEEThompsonRJVeltmanMWMThomasNSRobertsSet al
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
The 4 Nutrient Triggers That Actually Increase GLP-1 Secretion Most articles on this topic will hand you a list of foods and send you on your way
